Yawning behavior for preclinical drug evaluation

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 2, 1996, Pages 141-155

  Furukawa, T ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; PERGOLIDE; PHYSOSTIGMINE; PILOCARPINE; PIRIBEDIL; PSYCHOTROPIC AGENT; SCOPOLAMINE; TALIPEXOLE;

ANIMAL EXPERIMENT; BEHAVIOR; DOPAMINERGIC SYSTEM; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; NONHUMAN; PSYCHOMOTOR ACTIVITY; RAT; REVIEW; SEROTONINERGIC SYSTEM; YAWNING;

ANTIPARKINSON AGENTS; CHOLINERGIC AGENTS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; PITUITARY GLAND; PROLACTIN; PSYCHOTROPIC DRUGS; RECEPTORS, DOPAMINE D2; YAWNING;

EID: 0030012707     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Breese, G.R., Mueller, R.A., Lipton, M.A. Developmental neuropsychopharmacology. In: Psychopharmacology: A Generation of Progress. Lipton, M.A., DiMascio, A., Killam, K.F. (Eds.). Raven Press: New York 1978, 609-22.
2. Helton, D.R., Modlin, D.L., William, P.D. Behavioral characterization of the new potent nonselective dopamine agonist pergolide. Arzneim-Forsch/Drug Res 1992, 42: 885-90.
3. Koller, W.C., Weiner, W.J., Diamond, B.I., Nausieda, P.A., Klawans, H.L. The pharmacological evaluation of pergolide mesylate as a potential anti-Parkinson agent. Neuropharmacology 1980, 19: 831-7.
4. 2 dopamine receptor mechanisms in dopaminergic behaviors. Clin Neuropharmacol 1988, 11: 221-31.
5. Clements, J.A., Okimura, T., Smalstig, E.B. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning and stereotypic behavior. Arzneim-Forsch/Drug Res 1993, 43: 281-6.
6. Moore, K.E., Kelly, P.H. Biochemical pharmacology of mesolimbic and mesocortical dopaminergic neurons. In: Psychopharmacology: A Generation of Progress, Lipton, M.A., DiMascio, A.. Killam, K.F-. (Eds.). Raven Press: New York 1978, 221-34.
7. Duvoisin, R.C., Heikkila, R.E., Manzino, L. Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway. Neurology 1982, 32; 1387-91.
8. Yamada, K., Furukawa, T. Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 1980, 67: 39-43.
9. Collern, D., Isaacson, R.L., Bohus, B., Gispen, W.H. Limbic midbrain lesion and ACTH-induced excessive grooming. Life Sci 1977, 21: 393-402.
10. Bertolini, A., Vergoni, W., Gessa, G.L., Ferrari, W. Induction of sexual excitement by the action of adrenocorticotrophic hormone in brain. Nature 1969, 221: 667-9.
11. 4-10 on LH release, ovulation and behavior in the rabbit. Brain Res 1974, 80: 291-301.
12. Urba-Holmgren, R., Gonalez, R M., Holmgrem, B. Is yawning a cholinergic response? Nature 1977, 267: 261-2.
13. Ushijima, I., Yamada, K., Inoue, T., Tokunaga, T, Furukawa, T. Muscarinic and nicotinic effects on yawning and tongue protruding in the rat Pharmacol Biochem Behav 1984, 21: 297-300.
14. 2 receptors in yawning behavior in rats. Psychopharmacology 1986, 90: 9-13
15. Yamada, K., Furukawa, T. Behavioral studies on central dopaminergic neurons. Especially jumping, retching, body shaking and yawning behavior. J Pharmocobio-Dynamics 1980, 3: S16-8.
16. Ushijima, I., Mizuki, Y., Imaizumi, J. et al. Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine. Arch Int Pharmacodyn 1985, 273: 196-201.
17. Roberts, D.C.S., Zis, A.P. Ascending catecholamine pathways and amphetamine-induced locomotor activity: Importance of dopamine and apparent non-involvement of norepinephrine. Brain Res 1975, 93: 441-54.
18. Walters, J., Roth, R. Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmied Arch Pharmacol 1976, 296: 5-14.
19. Stahle, L., Ungerstedt, U. Yawning and suppression of exploration induced by dopamine agonists. No relation to extracellular striatal levels of dopamine. Pharmacol Biochem Behav 1990, 35: 201-9.
20. Stahle, L. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review. Psychopharmacology 1992, 106: 1-13.
21. 2-receptors after administration of SND 919 in rats. Naunyn-Schmied Arch Pharmacol 1989, 340: 21-5.
22. 2 receptors in yawning and stereotypy in rats. Psychopharmacology 1990, 100: 141-4.
23. Ungerstedt, U. Adipsia and aphagia after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 1971, 367(Suppl.): 95-117.
24. Arnt, J., Hyttel, J. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 1984, 60: 205-23.
25. Hjorth, S., Chark, D., Carlsson, A. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur J Pharmacol 1988, 152: 207-15.
26. Matsumoto, S., Yamada, K., Nagashima, M., Matsuo, N., Shirakawa, K., Furukawa, T. Potentiation by serotonergic inhibition of yawning induced by dopamine receptor agonists in rats. Pharmacol Biochem Behav 1989, 32: 815-8.
27. Sibley, D.R., Monsma, F.J. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992, 13: 61-9.
28. 3) as a target for neuroleptics. Nature 1990, 347: 146-51.
29. 3H-domperidone. Naunyn-Schmied Arch Pharmacol 1980, 315: 89-102.
30. 3H] hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 1992, 89: 8155-9.
31. 3 receptor expressed in transfected cell line. Eur J Pharmacol 1994, 266: 79-85.
32. 3 receptor agonists, 7-OH-DPAT and quinpirole. on yawning, stereotypy and body temperature in rats. Pharmacol. Biochem Behav 1995, 52: 503-8.
33. 3 receptor agonist, 7-OH-DPAT and quinpirole, on prolactin secretion in rats. Pharmacol Biochem Behav 1996, 53: 379-83.
34. 1-receptor agonist YM 796 evokes yawning and increases oxytocin secretion from the posterior pituitary gland in rats. Pharmacol Biochem Behav 1996, in press.
35. Fujikawa, M., Yamada, K., Nagashima, M., Furukawa, T. Involvement of β-adrenoceptors in regulation of the yawning induced by neuropeptides, oxytocin and α-melanocyte stimulating hormone, in rats. Pharmacol Biochem Behav 1995, 50: 339-43.
36. Yamada, K., Matsumoto, S., Nagashima, M., Kumagai, M., Kimura, H., Furukawa, T. Involvement of central β-adrenoceptors in the regulation of yawning responses. Naunyn-Schmied Arch Pharmacol 1989, 340: 26-30.
37. Yamada, K., Matsumoto, S., Nagashima, M., Shirakawa, K., Furukawa, T. Potentiation of yawning responses to the dopamine receptor agonists B-HT 920 and SND 919 by pindolol in the rat. J Neural Transm 1990, 79: 19-24.
38. Hokfelt, T., Fuxe, K., Goldstein, M., Johansson, O. Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain. Brain Res 1974, 66: 235-51.
39. Ward-Routledge. C., Marsden, C.A , Adrenaline in the CNS and the action of antihypertensive drugs. Trends Pharmacol Sci 1988, 9: 209-14.
40. Kimura, H., Yamada, K., Nagashima, M. et al. Role of adrenergic neuronal activity in the yawning induced by tacrine and NIK-247 in rats. Pharmacol Biochem Behav 1992, 43: 985-91.
41. Kimura, H., Yamada, K., Nagashima, M., Furukawa, T. Involvement of catecholamine receptor activities in modulating the incidence of yawning in rats. Pharmacol Biochem Behav 1996, in press.
42. Langer, S.Z. Presynaptic regulation of the release of cate-cholamines. Pharmacol Rev 1981, 32: 337-62.
43. Goshima, Y., Kubo, T., Misu, Y. Autoregulation of endogenous epinephrine release via presynaptic adrenoceptors in the rat hypothalamic slice. J Pharmacol Exp Ther 1985, 235: 248-53.
44. Yamada, K., Furukawa, T. The yawning elicited by α-melanocyte-stimulating hormone involves serotonergic-dopaminergic-cholinergic neuron link in rats. Naunyn-Schmied Arch Pharmacol 1981, 316: 155-60.
45. Okuyama, S., Shimamura, H., Hashimoto, S., Aihara, H. Relation between yawning behavior and central serotonergic neuronal system in rats. Naunyn-Schmied Arch Pharmacol 1987, 335: 667-72.
46. 3H]5-hydroxytryptamine. Neuroscience 1980, 5: 229-40.
47. Broch O.J., Jr. Marsden, C.A Regional distribution of monoamines in the corpus siriatum of the rat. Brain Res 1972, 38: 425-8.
48. Dourish, C.T., Cooper, S.J., Philips, S.R. Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat. Psychopharmacology (Berlin) 1985, 86: 175-81.
49. Miller, J.J., Richardson, T.L., Fibiger, H.C., McLennan, H. Anatomical and electrophysiological identification of a projection from the mesencephalic raphe to the caudate-putamen in the rat. Brain Res 1975, 97: 133-8.
50. Davies, J., Tongroach, P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 1978, 51: 91-100.
51. Ennis, C., Kemp, J.D., Cox, B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 1981, 36: 1515-20.
52. Olpe, H.R., Koella, W.P. The response of striatal cell upon stimulation of the dorsal and median raphe nuclei. Brain Res 1977, 122: 357-60.
53. Hervè, D., Shimon, H., Blanc, G. et al. Increased utilization of dopamine in the nucleus accumbens but not in the cerebral cortex after dorsal raphe lesion in the rat. Neurosci Lett 1979, 15: 127-33.
54. Ferrari, W., Gessa, G.L., Vargiu, L. Behavioral effects induced by intracisternally injected ACTH and MSH. Ann NY Acad Sci 1963, 104: 330-45.
55. Gispen, W.H., Wiegant, V.M., Greven, H.M., De Wied, D. The induction of excessive grooming in the rat by intraventricular application of peptides derived from ACTH: Structure-activity studies. Life Sci 1975, 17: 645-52.
56. Wood, P.L. Cheney, D.L., Costa, E. Modulation of the turnover rate of hippocampal acetylcholine by neuropeptides: Possible site of action of α-melanocyte-stimulating hormone, adrenocorticotrophic hormone and somatostatin. J Pharmacol Exp Ther 1979, 209: 97-103.
57. Melis, M.R., Stancampiano, R., Argiolas, A. Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. Pharmacol Biochem Behav 1992, 42: 61-6.
58. 8] Vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH-(1-24). Eur J Pharmacol 1987, 134: 221-4.
59. Yamada, K., Dermarest, K.T., Moore, K.E. Lack of effect of a behaviorally active dose of a melanotropine on biochemical indices of doparminergic neuronal activity in the rat. J Neural Transm 1982, 55: 189-99.
60. Wood, P.L., Besson, M.J., Giorguieff. M.F., Glowinski. J. Increase of hippocampal acetylcholine turnover rate and the stretching-yawning syndrome elicited by alpha-MSH and ACTH. Life Sci 1978, 22: 673-8.
61. Ben-Jonathan. N. Dopamine: A prolactin-inhibiting hormone. Endocrinol Rev 1985, 6: 564-89.
62. 2 dopamine receptor cDNA. Nature 1988, 336: 783-7.
63. 2 dopamine autoreceptor selective drugs: Do they really exist? Life Sci 1990, 47: 361-76.
64. Lemberger, L., Crabtree, R., Callaghan, J.T. Pergolide. a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther 1980, 27: 642-51.
65. 2 receptors after application of talipexole and SND 919. Eur J Pharmacol 1990, 179: 75-82.
66. Andén, N., Golembiowska-Nikitin, K., Thornström, U. Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively Naunyn-Schmied Arch Pharmacol 1982, 321: 100-4.
67. Pichler, L., Pifl, C., Hornykiewicz, O., Kobinger, W. The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats. Eur J Pharmacol 1987, 135: 239-42.
68. Eriksson, E., Svensson, K., Clark, D. The putative autoreceptor against B-HT 920 decreases nigral dopamine cell firing rate and prolactin release in rat. Life Sci 1985, 36: 1819-27.
69. Seutin, V., Scuvee-Moreau, J., Giesbers, L, Massotte, L., Dresse, A. Effect of BHT-920 on monoaminergic neurons of the rat brain: An electrophysioiogical in vivo and in vitro study. Naunyn-Schmied Arch Pharmacol 1990, 242: 502-7.
70. 2 receptors in rat striatum Eur J Pharmacol 1990, 187: 257-69.
71. 2 dopamine receptors. J Neural Transm 1990, 79: 209-14.
72. 2 receptor antagonistic activity. J Pharmacol Exp Ther 1995, 274: 329-36.
73. Fujikawa, M., Nagashima, M., Inoue, T., Yamada, K., Furukawa, T. Behavioral effects of OPC-14597, a potential antipsychotic agent, in rats. Pharmacol Biochem Behav 1996, in press.
74. Inoue, T., Domae, M., Yamada, K., Furukawa, T. Effects of a novel antipsychotic agent OPC-14597 on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996, 34(41): 73-4.
75. Ben-Jonathan, N. Dopamine: A prolactin-inhibiting hormone. Endocrinol Rev 1985, 6: 564-89.
76. Gudelsky, G.A., Porter, J.C. Release of newly synthesized dopamine into the hypophysial portal vasculature of the rat. Endocrinology 1979, 104: 583-7.
77. Seeman, P. Dopamine receptors in schizophrenia. In: Dopamine Receptor and Transporters: Pharmacology, Structure and Function. Niznik, H.B. (Ed.). Marcel Dekker, Inc.: New York 1994, 541-9.
78. Toru, M., Miura, S., Kudo, Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist, in schizophrenic patients. Neuropsychopharmacology 1994, 10: suppl. I, 122S.
79. Nielsen, J.A., Mena, E.E., Williams, I.H. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacrine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 1989, 173. 53-64.
80. Kojima, J., Yoshida, S., Ishii, Y., Fuji, K., Okumura, M. Effects of NIK 247 and 9-amino-1,2,3,4-tetrahydroacridine on scopolamine-induced amnesia, long-term potentiation and acetylcholinesterase. Eur J Pharmacol 1990, 183: 929.
81. Wanibuchi, F., Konishi, T., Harada, M. et al. Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azas-piro[4,5]decane derivatives. YM 796 and YM 954. Eur J Pharmacol 1990, 187: 479-86.